2013 Management Marketing Pharmaceuticals 
Harvard Business Review
JULY 30, 2015
A new research report from the Society of Digital Agencies finds that in the past year there has been a dramatic spike in the number of companies who no longer work with outside marketing agencies — 27 percent, up from 13 percent in the previous year. This continues a trend The Association of National Advertisers first reported in 2013.
Harvard Business Review
APRIL 3, 2017
The company was an eager user of my “cascading choices” framework for strategy that I have used for decades and written about extensively, most prominently in the 2013 book I wrote, with friend and colleague A.G. And Capabilities and Management Systems act as a reality check on the Where to Play and How to Win choice.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Harvard Business Review
JANUARY 13, 2014
But for 2013 he was only about 15 percent on target. But his 2013 forecasts were certainly within the realm of the possible; they just failed to materialize this year. But what happens when you want to look beyond today and examine your rivals or your market a few years from now? Obsessing over market leaders.
Harvard Business Review
OCTOBER 23, 2012
(Commenters suggest the obvious – if you don’t know who’s calling, don’t pick up the phone, and eventually the robo-marketers will get the message.) The contest opens on October 25 at robocall.challenge.gov , and will run through January 17, 2013. EXCUSEZ-MOI, MADAME, BUT HOW DO YOU MANAGE TO LOOK SO CHIC?
Harvard Business Review
NOVEMBER 30, 2017
A few outlier industries (notably pharmaceuticals, medical devices, and computers) prop up the sector’s aggregate performance; most others have experienced flat growth or outright declines in real GDP over the past two decades. But now the situation has reached such a tipping point that larger U.S. manufacturers are taking notice.
Harvard Business Review
AUGUST 23, 2012
These hurdles aren't unique to financial services — insurance, pharmaceuticals, health care and government all face regulation, to name a few examples. Employees, particularly those in the sales and marketing functions, need to know the rules of the road," Langford says. The risks and penalties are real.
Harvard Business Review
MAY 5, 2016
But peruse some of the recent headlines about Iran , and you might wonder whether the market’s potential was overstated. However, despite a weakened economy, political tensions, market uncertainty, and the lingering effects of sanctions, Iran remains an important opportunity for multinationals in emerging markets.
Expert insights. Personalized for you.
8 
Let's personalize your content